Cargando…

A novel twelve-gene signature to predict neoadjuvant chemotherapy response and prognosis in breast cancer

BACKGROUND: Accurate evaluation of the response to neoadjuvant chemotherapy (NAC) provides important information about systemic therapies for breast cancer, which implies pharmacological response, prognosis, and guide further therapy. Gene profiles overcome the shortcomings of the relatively limited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jin, Tian, Yuan, Liu, Wei, Zheng, Hong, Xi, Yuanyin, Yan, Yuzhao, Hu, Ying, Liao, Bin, Wang, Minghao, Tang, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629837/ https://www.ncbi.nlm.nih.gov/pubmed/36341435 http://dx.doi.org/10.3389/fimmu.2022.1035667

Ejemplares similares

Identification of Ferroptosis-Related Prognostic Signature and Subtypes Related to the Immune Microenvironment for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Xu, Yuhao, et al.
Publicado: (2022)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer
por: Fu, Changfang, et al.
Publicado: (2021)

A high interferon gamma signature of CD8(+) T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer
por: Li, Sen, et al.
Publicado: (2023)

A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma
por: Ouyang, Guoqing, et al.
Publicado: (2020)

SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival
por: Wang, Ruo-Xi, et al.
Publicado: (2022)

Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response
por: Xing, Ai-Yan, et al.
Publicado: (2021)

HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy
por: Saraiva, Diana P., et al.
Publicado: (2018)

Prognosis and Dissection of Immunosuppressive Microenvironment in Breast Cancer Based on Fatty Acid Metabolism-Related Signature
por: Tang, Yuhui, et al.
Publicado: (2022)

Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer
por: Lin, Guang-Tan, et al.
Publicado: (2022)

Construction and Validation of an Immune Infiltration-Related Gene Signature for the Prediction of Prognosis and Therapeutic Response in Breast Cancer
por: Peng, Yang, et al.
Publicado: (2021)

Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy
por: Ma, Youzhao, et al.
Publicado: (2023)

Evaluation of the ability of fatty acid metabolism signature to predict response to neoadjuvant chemoradiotherapy and prognosis of patients with locally advanced rectal cancer
por: Zhou, Han, et al.
Publicado: (2022)

Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC
por: Chi, Hao, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer
por: Zhu, Xudong, et al.
Publicado: (2019)

Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Chen, Li, et al.
Publicado: (2022)

Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
por: Zarotti, Cristina, et al.
Publicado: (2022)

Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma
por: Cai, Jialiang, et al.
Publicado: (2022)

Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures
por: Ji, Fei, et al.
Publicado: (2021)

Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy
por: Qiao, Yujin, et al.
Publicado: (2022)

Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients
por: Valdés-Ferrada, Javier, et al.
Publicado: (2020)

A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA
por: Yang, Mingyi, et al.
Publicado: (2022)

Prognosis stratification in breast cancer and characterization of immunosuppressive microenvironment through a pyrimidine metabolism-related signature
por: Luo, Yongzhou, et al.
Publicado: (2022)

An estrogen response-related signature predicts response to immunotherapy in melanoma
por: Lin, Min, et al.
Publicado: (2023)

Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer
por: Liu, Jianyu, et al.
Publicado: (2022)

A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients
por: Zheng, Tianzhi, et al.
Publicado: (2019)

Exploring biomarkers for prognosis and neoadjuvant chemosensitivity in rectal cancer: Multi-omics and ctDNA sequencing collaboration
por: Jiang, Xiu-Feng, et al.
Publicado: (2022)

Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma
por: Xu, Zhijie, et al.
Publicado: (2021)

Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma
por: Liu, Cong, et al.
Publicado: (2022)

Characterization of sialylation-related long noncoding RNAs to develop a novel signature for predicting prognosis, immune landscape, and chemotherapy response in colorectal cancer
por: Zhou, Mingxuan, et al.
Publicado: (2022)

Identification of immune related gene signature for predicting prognosis of cholangiocarcinoma patients
por: Zhang, Zi-jian, et al.
Publicado: (2023)

An Immune-Related Gene Signature for Predicting Neoadjuvant Chemoradiotherapy Efficacy in Rectal Carcinoma
por: Qian, Liwen, et al.
Publicado: (2022)

The prognostic role of a phospho-Stathmin 1 signature in breast cancer treated with neoadjuvant chemotherapy
por: Xie, Zhen, et al.
Publicado: (2022)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma
por: Liu, Yinan, et al.
Publicado: (2014)

Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer
por: Cui, Hanxiao, et al.
Publicado: (2023)

m(6)A RNA Methylation Regulator YTHDF1 Correlated With Immune Microenvironment Predicts Clinical Outcomes and Therapeutic Efficacy in Breast Cancer
por: Hu, Ying, et al.
Publicado: (2021)

Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
por: Jing, Shao-Wu, et al.
Publicado: (2022)

New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer
por: An, Junsha, et al.
Publicado: (2021)

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
por: He, Wenwu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m6pvuf9gjj8rsb15tf23f9nubb